Skip to main content
Autobound logo
Incyte10-K: Restructuring

Acquired exclusive global rights to tafasitamab from MorphoSys in Feb 2024, terminating prior collaboration.

Read at SEC EDGAR

What happened

This acquisition consolidates a key asset, moving from a partnership to full ownership.

Source

SEC EDGARFeb 10, 2026

Annual report (Form 10-K)

Incyte 10-K for FY2025

Filing excerpt

In February 2024, we entered into a purchase agreement with MorphoSys relating to tafasitamab.

sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htmRead the full source

Other signals in this filing (11)

Extracted by Autobound

From the Signal API record
Signal
10-K: Restructuring

What this signalsFilings often name leadership changes, deals and spending plans.

Period
FY2025
Fiscal year end
12/31
Filed
Feb 10, 2026

More from Incyte

Company page →

More 10-K signals at other companies

The full record

From the Signal API record

Details

CIK
879169
Accession number
0000879169-26-000010
Timeframe
Current year
Filing year
2026
Why it matters
Change management needs
Signal category
Workforce

Topics and mentions

Vendors

  • MorphoSys AG

Extraction

Confidence
High
Relevance
90%
Sentiment
Positive
Detected
Feb 17, 2026
signal_type
sec-10k
signal_subtype
restructuring

Use this data

Get every 10-K signal for Incyte and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”

    MCP setup guide

  2. Send it to your own tools

    The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.

    Signal API

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONThe record on this page and the API request

GET /v1/signals/c9dc29bc-359b-48b8-828e-aa01f962c7f0 returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.

{
  "signal_id": "c9dc29bc-359b-48b8-828e-aa01f962c7f0",
  "signal_type": "sec-10k",
  "signal_subtype": "restructuring",
  "detected_at": "2026-02-17T06:34:03.067+00:00",
  "company": {
    "name": "Incyte",
    "domain": "incyte.com"
  },
  "data": {
    "detail": "This acquisition consolidates a key asset, moving from a partnership to full ownership. This type of transaction often necessitates significant integration of commercial, regulatory, and supply chain systems, creating opportunities for IT and consulting vendors.",
    "metrics": {
      "timeframe": "current_year"
    },
    "summary": "Acquired exclusive global rights to tafasitamab from MorphoSys in Feb 2024, terminating prior collaboration.",
    "excerpts": "In February 2024, we entered into a purchase agreement with MorphoSys relating to tafasitamab.",
    "relevance": 0.9,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm",
    "filing_date": "2026-02-10",
    "filing_year": 2026,
    "fiscal_year_end": "12/31",
    "sales_relevance": "Change management needs",
    "signal_category": "workforce",
    "vendors_mentioned": [
      "MorphoSys AG"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.